Since its inception, iBET has partnered with pharma and agri-food companies in R&D projects.
R&D in Health & Pharma
Over the last 20 years, iBET has been developing R&D projects for international pharmaceutical companies, such as Bayer, Novartis, Merck, Sanofi, Abbvie, Apceth, AstraZeneca, Glaxo-Smith-Kline, Merck & Co., among others.
Health & Pharma R&D programs’ main areas include process development for protein production (including Monoclonal Antibodies); production of virus-based vaccines; viral vectors for gene therapy; development of tools and methodologies for cell therapy applications; pre-clinical research – novel 3D in vitro models for toxicology and disease models; and bioprocesses for pluripotent and adult Stem Cells.
Pharma Satellite Laboratories
Pharma companies have become valuable partners of iBET over the years, as our scientific and technical competences grew in excellence and always principled by a culture of delivering. With a solid foundation based on trust, the reinforcement of such partnerships led to the creation of the Satellite Laboratories concept in 2009.
Satellite Laboratories have fully dedicated laboratory spaces and teams exclusively committed to research within the network of each company and comprise scientists jointly recruited by the company and iBET.
Today, there are four Satellite Laboratories at iBET: Bayer, Merck, Novartis and Sanofi. Know more in the link below.
R&D in Food & Health
The Food & Health division offers R&D services for partners from academia to SMEs, food industries and biopharma and has a long-standing cooperation with national and international public/private partnerships, enabling access to a larger range of equipment and facilities.
The division brings together different areas of expertise, including the characterization and validation of bioactivity of components in different food matrices: food, industrial by-products and nutraceuticals, using different approaches: from chemical and instrumental analysis to human intervention studies. This work is supported by R&D laboratories, analytical services and a semi-pilot technological platform allowing a wide offer of sensitive and selective analytical methodologies.
